Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01466-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Chiara Pellicano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Biomarkers, Bacterial Translocation, Haptoglobins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.
Abstract (Originalsprache)
Gastrointestinal (GI) tract involvement affects up to 90% of Systemic sclerosis (SSc) patients. The presence of GI symptoms is assessed by the University of California, Los Angeles, and Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT 2.0). Microbial translocation (MT) is reported in SSc patients consequently to increased intestinal permeability due to intestinal damage (ID) and dysbiosis. Aim of this study was to assess circulating levels of LBP and EndoCab IgM (markers of MT), IL-6 (marker of inflammation), I-FABP and Zonulin (markers of ID) in a cohort of SSc patients and healthy controls (HC). Moreover, we aimed to correlate these parameters with severity of GI symptoms. UCLA SCTC GIT 2.0 questionnaire was administered to 60 consecutive SSc patients. Markers of MT, inflammation and ID were evaluated in SSc patients and HC. SSc patients had higher median value of markers of MT, inflammation and ID than HC. The logistic regression analysis showed LBP as the only variable associated with an UCLA total score “moderate-to-very severe” [OR 1.001 (CI 95%: 1.001–1.002), p < 0.001]. The logistic regression analysis showed LBP [OR 1.002 (CI 95%: 1.001–1.003), p < 0.01] and disease duration [OR 1.242 (CI 95%: 1.023–1.506), p < 0.05] as variables associated with UCLA distension/bloating “moderate-to-very severe”. The logistic regression analysis showed LBP as the only variable associated with UCLA diarrhea “moderate-to-very severe” [OR 1.002 (CI 95%: 1.001–1.003), p < 0.01]. SSc patients with dysregulation gut mucosal integrity expressed by high levels of MT and ID biomarkers had more severe GI symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy.
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185, Rome, Italy.
- Department of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy. edoardo.rosato@uniroma1.it.
Förderung
- Università degli Studi di Roma La Sapienza
Zitieren
APA
Pellicano, C., Oliva, A., Colalillo, A., Gigante, A., D'Aliesio, E., Al Ismail, D., Miele, M. C., Cianci, R., Mastroianni, C. M., & Rosato, E. (2024). Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01466-1
Vancouver
Pellicano C, Oliva A, Colalillo A, Gigante A, D'Aliesio E, Al Ismail D, et al. Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01466-1
BibTeX
@article{Pellicano2024,
author = {Pellicano, Chiara and Oliva, Alessandra and Colalillo, Amalia and Gigante, Antonietta and D'Aliesio, Elisa and Al Ismail, Dania and Miele, Maria Claudia and Cianci, Rosario and Mastroianni, Claudio Maria and Rosato, Edoardo},
title = {Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01466-1}
}
EUVIMED